Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting

By sjmartinez • March 17, 2023

Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, Cheng WW, Flahavan EM, Kota V, Greenwald DR. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting. Clin Lymphoma Myeloma Leuk. 2023 Feb 11:S2152-2650(23)00037-X. doi: 10.1016/j.clml.2023.02.002. Epub ahead of print. PMID: 36925388.

Tags: Acute myeloid leukemia, Azacitidine, Decitabine, Hematology/Oncology, Outcomes research, Publications, Real-word data

Related Posts

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu[...]

Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns[...]

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon[...]